Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida — Clinical Trial Site

155 Registered trials

63 Currently recruiting

Organisation

Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida

Location

Lleida, Spain

Identifier

ORG-100032779

Address

Avinguda De L'alcalde Rovira Roure 80, 25196, Spain

Departments

-
#034002 Oncología Médica
#2320: servicio de neurología
#2505: Servicio de oncología médica
1320: Hematologia
3401-Gastroenterología
7201: Neurology
Anaesthesiology
Anaesthesiology and Pain Management
Anestesiology
Cardiología
Cardiology
Cardiology Service
cirugia
Departamento de Neurología
Endocrinology
Endocrinology and metabolism
Endocrinology and nutrition
ES006:Pediatría
Gastroenterology
Haematology
Hematología
Hematology
Hematology and Oncology
Institut de Recerca Biomedica Lleida (IRB Lleida).
Intensive Care
Intensive Medicine
Internal Medicine
MEDICAL ONCOLOGY
Medicina Interna
NA
Nefrología
Neonatology
Nephrology
Neprology
Neumología
Neurología
Neurology
Not applicable
Obstetrician and Gynecologist
Oncolgy
Oncología
Oncology
Oncology department
Oncology Service
Pulmonology
Respiratory medicine
Servicio de Endocrinología
Servicio de Nefrologia
Servicio de Neurología
Servicio de Oncologia
Servicio de Oncología Médica
Surgery
Thoracic Oncology
Traumatology

Clinical trials at this site (155)

Search interface

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending

2024-518821-13-00 Non-cystic Fibrosis Bronchiectasis 4
“USE OF A FIBRIN ADHESIVE TO REDUCE ESOPHAGOYEJUNAL ANASTOMOSIS DEHISCENCE IN TOTAL GASTRECTOMIES FOR CANCER: RANDOMIZED AND MULTICENTER STU… Pending

2024-519529-40-00 ESOPHAGOYEJUNAL ANASTOMOSIS DEHISCENCE IN TOTAL GASTREC 5
Artesunate, sulfasalazine polyunsaturated fatty acids, and iron in patients with solid tumors. Pending

2024-519602-12-01 Cancer 3
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
A study to evaluate safety and explore efficacy of new lipase NHS7108 compared with pancrelipase in adult participants with exocrine pancre… Pending

2025-521816-20-00 Exocrine Pancreatic Insufficiency 4
A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending

2025-522791-92-00 Neoplasm Metastasis 5
A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0… Pending

2025-523058-16-00 Skin Toxicities Associated with Epidermal Growth Factor 4
EFFICACY OF PROPRANOLOL IN TRAUMATIC BRAIN INJURY PATIENTS ADMITTED TO THE ICU: A PROSPECTIVE, RANDOMIZED, TRIPLE-BLIND STUDY (ProP TBI in I… Pending

2025-524194-17-00 Head injury 5
Optimizing Aspirin Use for Preeclampsia Prevention Pending

2025-524646-94-00 Obstetrics – Preeclampsia 11
SIE-1 Recruiting

2025-523269-31-00 Hormone receptor-positive early breast cancer in post-m 3 2026-06-02
A study to investigate efficacy, safety, immunogenicity, and pharmacokinetics of GSK3862995B following repeat doses in participants with bro… Recruiting

2025-522892-27-00 Bronchiectasis 4 2026-03-21
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity … Recruiting

2025-521562-95-00 Previously Untreated Advanced (Unresectable or Metastat 5 2025-12-30
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Efficacy and safety of Ropivacaine injection in the management of post-operative pain: A comparison of plane block versus wound infiltration… Recruiting

2024-511406-23-00 lumbar arthrodesis 6 2025-11-13
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting

2024-514135-17-00 Immunoglobulin A Nephropathy 5 2024-11-28
A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Recruiting

2022-501890-38-00 acute ischemic stroke 4 2024-02-16
Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera… Recruiting

2022-501220-14-00 epithelial ovarian, primary peritoneal, or fallopian tu 4 2023-10-17
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting

2022-500544-38-00 Advanced Breast Cancer 5 2023-06-05